Brief: U.S. FDA Accepts Viatris New Drug Application For Fast-Acting Meloxicam For The Treatment Of Moderate-To-Severe Acute Pain
18/05/2026 14:21
May 18 (Reuters) - Viatris Inc VTRS.O: U.S. FDA ACCEPTS VIATRIS NEW DRUG APPLICATION FOR FAST-ACTING MELOXICAM FOR THE TREATMENT OF MODERATE-TO-SEVERE ACUTE PAIN VIATRIS INC - FDA SETS PDUFA GOAL DATE OF DEC. 27, 2026 FOR VIATRIS FAST-ACTING MELOXICAM Source text: ID:nPn385jVXa Further company coverage: VTRS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Viatris
See all newsBrief: Viatris Receives U.S. FDA Approval For Ryzumvi® For The Treatment Of Presbyopia
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Deals of the day-Mergers and acquisitions
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal